CD19 and neoplasm: Similarly, transfection of a nonviral vector containing the CCR7 receptor, along with a high-affinity CD16 Fc receptor and an anti-CD19 CAR, resulted in enhanced survival and superior tumor control in humanized mice bearing lymphoma tumors [128].